Gilead Sciences is trading at $172.85, up 3.22%, amid biotech strength and broader risk-on trading. - The sector trend reports XBI up 2.13%. - Gilead announced 23 presentations at December’s ASH meeting, but available reporting does not link the announcement to today’s share move. - The October 29 earnings beat and raised guidance are earlier background, not a new November 4 catalyst.